Opendata, web and dolomites

Lymphit

LYMPHIT: an innovative easy-to-use and cost-efficient diagnostic microneedle patch for the early detection of Lymphedema

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Lymphit project word cloud

Explore the words cloud of the Lymphit project. It provides you a very rough idea of what is the project "Lymphit" about.

inadequate    lymphedema    conservative    optimization    fluorescent    clinical    worldwide    profile    healthcare    fluorescence    limb    safety    chronic    dissolving    medical    optically    oncologic    fda    occurring    25    disease    social    50    global    care    painless    revenues    fluids    selectively    acute    serious    diagnosis    swelling    commercialized    roi    secondary    clinicians    stage    generating    validation    prescribe    quantitatively    agent    lymphatic    microneedles    icg    function    practitioners    398m    debilitation    fold    company    contain    minimally    outlined    later    64    dicronis    patients    markets    patches    market    patient    decreasing    extremely    polymeric    tracking    status    earliest    complications    life    productivity    fifth    treatments    detect    quality    lymphit    sme    tool    reduce    completion    complete    detection    decay    worsening    disrupting    boost    ftes    approved    first    scalable    progressive    additional    physical    empowering    psychological    accumulation    instrument    diagnostic    invasive    manner   

Project "Lymphit" data sheet

The following table provides information about the project.

Coordinator
DICRONIS SAGL 

Organization address
address: VIA CAMPAGNA 57
city: MONTEGGIO
postcode: 6998
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.dicronis.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DICRONIS SAGL CH (MONTEGGIO) coordinator 50˙000.00

Map

 Project objective

Lymphedema is a chronic condition, outlined by a progressive accumulation of fluids in a limb, leading to great physical and psychological debilitation of the affected patient and often occurring secondary to oncologic treatments. There is not early diagnosis for lymphedema. Current diagnostic methods are highly inadequate and detect the disease only at an advanced stage, leading to serious complications, greatly decreasing quality-of-life of the patients while increasing healthcare costs. In response to this challenge, Dicronis has developed a diagnostic tool (LYMPHIT) based on a painless and minimally-invasive delivery of ICG, an FDA approved fluorescent agent, with an extremely high safety profile, integrated into polymeric dissolving microneedles patches which allows determining the status of the lymphatic system by optically measurement of the fluorescence decay. LYMPHIT enables patients and clinicians the earliest possible detection of lymphedema, by quantitatively tracking the function of the lymphatic system in a painless, easy-to-use and highly-scalable manner. LYMPHIT will be disrupting in the market by empowering medical practitioners to timely and selectively prescribe conservative treatments, which can contain or avoid a worsening of the swelling in the affected limb. Therefore, LYMPHIT will reduce lymphedema treatments costs up to 50% and reduce 10-fold the social costs associated to productivity loss, both of them associated with late stage lymphedema. Upon completion of the project, LYMPHIT will boost the growth of our company generating additional 64 FTEs, revenues of €398M and a ROI of 10.25 by the fifth year after Phase 2 execution. With the help of the SME instrument, Dicronis aims to complete the product optimization and clinical validation so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the lymphedema patient´s quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LYMPHIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More